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GUEST EDITORIAL

Introduction to Personalized Medicine
Readers may have noticed a new
healthcare catchphrase gracing magazine
covers and even the front page of the New
York Times: “personalized medicine.”1 But
what does it mean and how will it change
healthcare? According to the President’s
Council of Advisors on Science and
Technology, ‘Personalized medicine refers
to the tailoring of medical treatment to the
individual characteristics of each patient.’2
Personalized medicine is important
because of several emerging clinical and
financial trends in healthcare. As a result,
there is a strong impetus for personalized
medicine, which can succeed if we can
find a way to break down the silos that
have traditionally separated clinical and
financial world views.
The clinical trends important to
personalized medicine are evidencebased medicine, the genomic revolution,
and big data. Evidence-based medicine
is behind the push to reduce variation in
care, making providers accountable for
delivering treatments that are grounded
in scientific evidence. The genomic
revolution refers to our ability to quickly
and cheaply sequence the human genome
and to determine the biological basis of
behavior and disease. Big data refers to
our ability to create large data sets and
implement automated systems, like IBM’s
Watson, to sort through and make sense of
all the information we collect.
Personalized medicine also capitalizes on
emerging financial trends in healthcare–
pay for performance, bundled payments,
and expansion of affordable care. Pay for
performance is where the rubber meets
the road for evidence based healthcare–no
outcome, no income. Bundled payments
refers to the recognition that medical care,
like a hospitalization for a heart attack,
should be paid for in a lump sum rather
than as separate line item bills for the

hospital stay, EKGs, and aspirin. The need
to deliver affordable care is at the heart of
Affordable Care Act, which aims to expand
health insurance coverage to the uninsured
by finding savings in other parts of the
healthcare system.
Personalized medicine ties together the
clinical trends of evidence-based medicine,
the genomic revolution, and big data with
the financial trends of pay for performance,
bundled payments, and expansion of
affordable care. Evidence-based medicine
gives payers reassurance that individuals
are getting the most appropriate treatment
based on published guidelines. Payment
rates for the expected cost of an entire
course of care should be as personalized
as the treatments they finance, to ensure
that provider compensation is adequate and
provides the correct incentives–that will
require smart bundled payments. Providers
will collect data on their patients, compare
outcomes to those in the published
literature to benchmark their performance,
and researchers can use the same data to
refine the published literature on outcomes
and costs for this population, i.e. big data.
Payers could use the same data to provide
extra incentives for high-performance
care as demonstrated through superior
outcomes, which is the goal of pay for
performance. This process will ultimately
save costs for patients and allow us to
sustainably cover the entire population
with health insurance, the essence of
affordable care.
So what’s the problem? In our current
fragmented, fee-for-service medical
system, the vision I outlined has yet to
become a reality. Personalized medicine
is a bundled product. However, payers
often pay for each diagnostic, drug, and
device separately. We all know that the
informatics needed to connect a diagnostic
to the therapy regimen and outcomes

just doesn’t exist in most healthcare
environments. Finally, payers are wary
of the idea of paying more upfront for a
new technology that promises savings in
the future—they are more comfortable
focusing on the cost savings in the here and
now by denying reimbursement for a new
test outright, requiring prior authorizations,
or a high degree of patient cost sharing in
order to contain costs.
So what’s the solution? Well, we could
wait for the integrated, affordable
healthcare system of our dreams. If we
are talking about today, however, and
not the year 2100, the answer is to take
a more integrated perspective. What
will get payers to agree to pay for a new
technology when technology has been at
the heart of our cost containment crisis?
Data that shows that personalized medicine
can save costs by avoiding treatments that
will not work. What will get providers to
order those tests, and then actually use
the results? Properly designed incentives
that compare the expected outcomes
and costs of care with patients’ actual
experience. Patients will also need to be
convinced of the need to become involved
in personalized treatment decisions. Highdeductible cost sharing and opaque prices
mean that patients are getting tired of
being surprised with large bills for care
that they consider necessary. The promise
of personalized medicine rests on the
ability of scientists and financial analysts
to collaborate to deliver this critical
information in an impactful way.
I have seen these issues play out on the
ground level in my own research. In one
recent study, funded by MDxHealth,
I was part of a team that investigated
the potential cost savings from a new
technology for the problem of unnecessary
prostate biopsies.3 MDxHealth’s product,
ConfirmDx for prostate cancer, is designed

Population Health
Matters
to reduce the cost associated with repeat
biopsies to diagnose prostate cancer.
Using a budget impact model, we found
that there was the potential for the test
to be cost saving when accounting for
the costs of repeated biopsies and the
costs of the side effects of this invasive
diagnostic procedure. However, the
potential for cost savings were limited by
the need to conform to the one-year time
horizon common in U.S. managed care.
In addition, prospective trials that collect
clinical and financial data on the outcomes
and cost of care will be needed to convince
payers and providers that our results are
credible. New payment models are needed

to correctly align the incentives of patients,
providers, and payers so that the individual
responsible for the cost of care shares in
the benefits of any cost savings.
While there are barriers to studying and
implementing personalized medicine, the
underlying forces motivating this new
platform for healthcare are even stronger.
The questions of how much technology
should cost, who should pay, and the
value of any new technology have taken
on a heightened significance in the age of
tighter budgets. Personalized medicine
holds the promise of moving from a world
of reducing waste on average to reducing

Vol. 26 No. 2 | SPRING 2013

waste on a patient-by-patient basis,
which means a much greater potential for
savings. In order to realize this vision, it
will be necessary to collect both clinical
and financial evidence in order to make the
case for personalized medicine. We can
then achieve our goals of treating patients
as individuals, and doing so at a price we
can afford. 
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